FDA-Approved Peptide Drug List (Complete, Updated)
The FDA has approved roughly 100 peptide-based drugs since insulin first reached patients in 1922. That number continues to grow: peptides accounted for about 10% of all new FDA drug approvals between 2020 and 2024, and the peptide therapeutics market is projected to exceed $49 billion by 2026.
The FDA has approved roughly 100 peptide-based drugs since insulin first reached patients in 1922. That number continues to grow: peptides accounted for about 10% of all new FDA drug approvals between 2020 and 2024, and the peptide therapeutics market is projected to exceed $49 billion by 2026.
This page catalogs every major FDA-approved peptide medication, organized by therapeutic category. Each entry includes the generic name, brand name(s), approval year, indication, and manufacturer. We update this list as new approvals occur.
For a broader look at peptide regulation, see our guide on which peptides are FDA-approved.
Table of Contents
- How We Define "Peptide Drug"
- Diabetes and Metabolic Disorders
- Oncology
- Bone and Calcium Disorders
- Cardiovascular and Hematologic
- Reproductive Health and Fertility
- Gastrointestinal Disorders
- Neurological and Pain
- Infectious Disease
- Immune and Inflammatory Disorders
- Rare and Genetic Diseases
- Diagnostic and Imaging Agents
- Dermatology and Sexual Health
- Recent Approvals: 2023--2026
- The Approval Timeline: Peptide Drugs by Decade
- FAQ
- The Bottom Line
- References
How We Define "Peptide Drug"
For this list, we include drugs where the active ingredient is a peptide (typically 2--100 amino acids) or a close peptide analog. We include peptide-drug conjugates and PEGylated peptides. We exclude monoclonal antibodies (which are full-length proteins), recombinant proteins larger than ~200 amino acids (like erythropoietin or interferon), and non-peptide small molecules that target peptide receptors (like orforglipron). Insulin and its analogs are included as the foundational peptide drugs, though they sit at the boundary between peptide and small protein.
Diabetes and Metabolic Disorders
GLP-1 receptor agonists have transformed diabetes and obesity treatment. This category also includes insulin, amylin analogs, and the dual/triple agonists that represent the newest generation.
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Insulin (human, recombinant) | Humulin, Novolin | 1982 | Type 1 and Type 2 diabetes | Eli Lilly / Novo Nordisk |
| Insulin lispro | Humalog | 1996 | Diabetes (rapid-acting) | Eli Lilly |
| Insulin aspart | NovoLog, Fiasp | 2000, 2017 | Diabetes (rapid-acting) | Novo Nordisk |
| Insulin glargine | Lantus, Toujeo, Basaglar | 2000 | Diabetes (long-acting basal) | Sanofi / Eli Lilly |
| Insulin detemir | Levemir | 2005 | Diabetes (long-acting basal) | Novo Nordisk |
| Insulin degludec | Tresiba | 2015 | Diabetes (ultra-long-acting basal) | Novo Nordisk |
| Insulin glulisine | Apidra | 2004 | Diabetes (rapid-acting) | Sanofi |
| Pramlintide | Symlin | 2005 | Type 1 and Type 2 diabetes (adjunct to insulin) | AstraZeneca (originally Amylin Pharmaceuticals) |
| Exenatide | Byetta, Bydureon | 2005, 2012 | Type 2 diabetes | AstraZeneca |
| Liraglutide | Victoza, Saxenda | 2010, 2014 | Type 2 diabetes; chronic weight management | Novo Nordisk |
| Lixisenatide | Adlyxin | 2016 | Type 2 diabetes | Sanofi |
| Dulaglutide | Trulicity | 2014 | Type 2 diabetes | Eli Lilly |
| Semaglutide | Ozempic, Rybelsus, Wegovy | 2017, 2019, 2021 | Type 2 diabetes; chronic weight management | Novo Nordisk |
| Tirzepatide | Mounjaro, Zepbound | 2022, 2023 | Type 2 diabetes; chronic weight management | Eli Lilly |
| Tesamorelin | Egrifta | 2010 | HIV-associated lipodystrophy (excess abdominal fat) | Theratechnologies |
Semaglutide and tirzepatide are the two fastest-growing prescription drugs in history by revenue. In 2025, the FDA expanded semaglutide's indication to include cardiovascular risk reduction and slowing kidney disease progression in type 2 diabetes patients. An oral 25 mg semaglutide formulation for weight loss (Wegovy oral) was also approved.
For more on the differences between these drugs, see our comparisons of semaglutide vs. tirzepatide and Ozempic vs. Wegovy.
Oncology
Peptide drugs in oncology work primarily through three mechanisms: suppressing hormone-driven tumor growth (GnRH analogs), targeting somatostatin receptors on neuroendocrine tumors, and delivering radioactive payloads directly to cancer cells (peptide receptor radionuclide therapy).
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Leuprolide | Lupron, Eligard, Fensolvi | 1985 | Prostate cancer, endometriosis, uterine fibroids, central precocious puberty | AbbVie / Tolmar |
| Goserelin | Zoladex | 1989 | Prostate cancer, breast cancer, endometriosis | AstraZeneca |
| Octreotide | Sandostatin, Sandostatin LAR, Mycapssa | 1988, 1998, 2020 | Acromegaly, carcinoid tumors, VIPomas | Novartis / Amryt |
| Lanreotide | Somatuline Depot | 2007 | Acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | Ipsen |
| Pasireotide | Signifor, Signifor LAR | 2012, 2014 | Cushing's disease, acromegaly | Recordati (originally Novartis) |
| Degarelix | Firmagon | 2008 | Advanced prostate cancer | Ferring Pharmaceuticals |
| Histrelin | Vantas, Supprelin LA | 2004, 2007 | Prostate cancer, central precocious puberty | Endo Pharmaceuticals |
| Triptorelin | Trelstar | 2000 | Advanced prostate cancer | Verity/Debiopharm |
| Abarelix | Plenaxis | 2003 | Advanced prostate cancer (withdrawn from US market 2005) | Praecis Pharmaceuticals |
| Romidepsin | Istodax | 2009 | Cutaneous T-cell lymphoma, peripheral T-cell lymphoma | Celgene (BMS) |
| Lutetium Lu-177 dotatate | Lutathera | 2018 | GEP-NETs (peptide receptor radionuclide therapy) | Novartis (Advanced Accelerator Applications) |
| Gallium Ga-68 dotatate | Netspot | 2016 | Imaging of somatostatin receptor-positive NETs (diagnostic) | Advanced Accelerator Applications |
| Gallium Ga-68 dotatoc | Detectnet | 2019 | Imaging of somatostatin receptor-positive NETs (diagnostic) | RadioMedic |
| Copper Cu-64 dotatate | Detectnet (Cu-64) | 2020 | Imaging of NETs | --- |
| Motixafortide | Aphexda | 2023 | Stem cell mobilization (with G-CSF) prior to autologous transplant in multiple myeloma | BioLineRx |
The GnRH agonists (leuprolide, goserelin, triptorelin, histrelin) work by initially stimulating and then desensitizing pituitary GnRH receptors, shutting down testosterone or estrogen production. This "chemical castration" effect makes them cornerstone treatments for hormone-sensitive cancers.
Bone and Calcium Disorders
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Calcitonin (salmon) | Miacalcin, Fortical | 1986 | Postmenopausal osteoporosis, Paget's disease, hypercalcemia | Various |
| Teriparatide | Forteo, Bonsity | 2002 | Osteoporosis (high fracture risk) | Eli Lilly / Pfenex |
| Abaloparatide | Tymlos | 2017 | Postmenopausal osteoporosis (high fracture risk) | Radius Health |
| Palopegteriparatide | Yorvipath | 2024 | Hypoparathyroidism in adults | Ascendis Pharma |
Teriparatide is a synthetic fragment of parathyroid hormone (PTH amino acids 1--34). Unlike anti-resorptive drugs that slow bone breakdown, teriparatide and abaloparatide are anabolic --- they stimulate new bone formation. Palopegteriparatide, approved in 2024, is a PEGylated PTH(1--34) prodrug that became the first treatment specifically approved for hypoparathyroidism.
Cardiovascular and Hematologic
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Vasopressin | Vasostrict | 2014 (current formulation) | Vasodilatory shock (ICU setting) | Endo/Par |
| Desmopressin | DDAVP, Stimate, Nocdurna | 1978 | Diabetes insipidus, hemophilia A/von Willebrand disease (bleeding), nocturnal enuresis | Various |
| Terlipressin | Terlivaz | 2022 | Hepatorenal syndrome type 1 | Mallinckrodt |
| Nesiritide | Natrecor | 2001 | Acute decompensated heart failure | Janssen (J&J) |
| Eptifibatide | Integrilin | 1998 | Acute coronary syndrome, percutaneous coronary intervention | Merck (originally COR Therapeutics) |
| Bivalirudin | Angiomax | 2000 | Anticoagulation during PCI, HIT | The Medicines Company |
Desmopressin, a synthetic analog of vasopressin (with modifications that boost antidiuretic activity and eliminate vasopressor effects), has accumulated six separate FDA approvals across different indications and formulations --- more than any other peptide by approval count.
Reproductive Health and Fertility
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Oxytocin | Pitocin | 1980 (synthetic; natural use predates) | Labor induction, postpartum hemorrhage control | Various |
| Nafarelin | Synarel | 1990 | Endometriosis, central precocious puberty | Pfizer |
| Ganirelix | Ganirelix Acetate Injection | 1999 | GnRH antagonist for controlled ovarian stimulation in IVF | Organon (MSD) |
| Cetrorelix | Cetrotide | 2000 | GnRH antagonist for controlled ovarian stimulation | EMD Serono |
| Carbetocin | Duratocin (available internationally) | Not FDA-approved (WHO Essential Medicine) | Prevention of postpartum hemorrhage | Ferring |
GnRH antagonists (ganirelix, cetrorelix) prevent premature ovulation during IVF cycles by blocking pituitary GnRH receptors without the initial stimulatory "flare" that GnRH agonists cause.
Gastrointestinal Disorders
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Linaclotide | Linzess | 2012 | IBS with constipation (IBS-C), chronic idiopathic constipation | AbbVie (Ironwood/Allergan) |
| Plecanatide | Trulance | 2017 | IBS-C, chronic idiopathic constipation | Salix Pharmaceuticals |
| Teduglutide | Gattex | 2012 | Short bowel syndrome (dependence on parenteral nutrition) | Takeda |
| Larazotide | --- | Phase 3 completed | Celiac disease (investigational) | 9 Meters Biopharma |
Linaclotide and plecanatide are guanylate cyclase-C agonists --- 14-amino-acid peptides that work locally in the gut to increase fluid secretion and accelerate transit. They're minimally absorbed into the bloodstream, which limits systemic side effects. Teduglutide is an analog of GLP-2 that promotes intestinal adaptation and growth.
Neurological and Pain
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Ziconotide | Prialt | 2004 | Severe chronic pain (intrathecal) | Jazz Pharmaceuticals |
| Difelikefalin | Korsuva | 2021 | CKD-associated pruritus (chronic itch in dialysis patients) | Vifor Pharma / CSL |
| Trofinetide | Daybue | 2023 | Rett syndrome | Acadia Pharmaceuticals |
Ziconotide is a synthetic version of a 25-amino-acid peptide from the cone snail Conus magus. It blocks N-type calcium channels in the spinal cord and is delivered directly into cerebrospinal fluid via an intrathecal pump. It remains one of only a handful of non-opioid options for severe chronic pain.
Trofinetide is a synthetic tripeptide analog of IGF-1's terminal tripeptide. Approved in 2023, it became the first drug ever approved for Rett syndrome.
Infectious Disease
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Enfuvirtide | Fuzeon | 2003 | HIV-1 infection (treatment-experienced patients) | Roche/Genentech |
| Vancomycin | Vancocin | 1958 | Serious Gram-positive infections, C. difficile colitis | Various |
| Daptomycin | Cubicin | 2003 | Skin infections, S. aureus bacteremia | Merck (originally Cubist) |
| Telaprevir | Incivek | 2011 | Hepatitis C (withdrawn 2014; superseded by newer agents) | Vertex |
| Boceprevir | Victrelis | 2011 | Hepatitis C (discontinued) | Merck |
Enfuvirtide is a 36-amino-acid peptide that blocks HIV entry into cells by preventing the conformational change in gp41 needed for viral-cell membrane fusion. While effective, its twice-daily subcutaneous injection requirement limited its widespread adoption.
Note: Vancomycin and daptomycin are technically cyclic lipopeptide antibiotics rather than traditional peptides, but they're widely classified alongside peptide drugs.
Immune and Inflammatory Disorders
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Glatiramer acetate | Copaxone, Glatopa | 1996 | Relapsing forms of multiple sclerosis | Teva / Sandoz |
| Icatibant | Firazyr | 2011 | Acute hereditary angioedema attacks | Takeda (originally Jerini) |
| Pegcetacoplan | Empaveli | 2021 | Paroxysmal nocturnal hemoglobinuria (PNH) | Apellis Pharmaceuticals |
| Zilucoplan | Zilbrysq | 2023 | Generalized myasthenia gravis (anti-AChR antibody positive) | UCB Pharma |
| Voclosporin | Lupkynis | 2021 | Lupus nephritis | Aurinia Pharmaceuticals |
Glatiramer acetate is unusual --- it's a random polymer of four amino acids (glutamic acid, lysine, alanine, tyrosine) that mimics myelin basic protein. After nearly three decades on the market, it remains a first-line therapy for relapsing MS, though its exact mechanism is still debated.
Rare and Genetic Diseases
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Setmelanotide | Imcivree | 2020 | Genetic obesity (POMC, PCSK1, LEPR deficiency) | Rhythm Pharmaceuticals |
| Vosoritide | Voxzogo | 2021 | Achondroplasia (short-limbed dwarfism) in children | BioMarin |
| Elamipretide | Forzinity | 2025 | Barth syndrome | Stealth BioTherapeutics |
Setmelanotide is an MC4R agonist --- it activates the same melanocortin receptor pathway that alpha-MSH uses to regulate appetite. But unlike weight-loss drugs for the general population, setmelanotide is approved only for patients with genetically confirmed defects in the leptin-melanocortin pathway.
Elamipretide, approved in 2025, targets the inner mitochondrial membrane. It became the first disease-specific treatment for Barth syndrome, a rare genetic condition causing cardiomyopathy and muscle weakness.
Diagnostic and Imaging Agents
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Pentetreotide (Indium In-111) | OctreoScan | 1994 | Imaging of neuroendocrine tumors | Mallinckrodt |
| Gallium Ga-68 dotatate | Netspot | 2016 | PET imaging of somatostatin receptor-positive NETs | Advanced Accelerator Applications |
| Gallium Ga-68 dotatoc | Detectnet | 2019 | PET imaging of NETs | RadioMedic |
| Gallium Ga-68 gozetotide | Locametz | 2022 | PET imaging of PSMA-positive prostate cancer | Novartis |
| Fluoroestradiol F-18 | Cerianna | 2020 | PET imaging of ER-positive breast cancer | Zionexa |
| Pegulicianine | Lumisight | 2024 | Fluorescence imaging of breast cancer during lumpectomy | Lumicell |
| Secretin (synthetic) | SecreFlo, ChiRhoStim | 2002, 2004 | Diagnostic: pancreatic function testing, aid in MRCP imaging | Various |
| Cosyntropin | Cortrosyn | 1970 | ACTH stimulation test (adrenal function) | Various |
| Pentagastrin | --- | Historical use | Diagnostic: gastric acid secretion testing (largely replaced) | --- |
Peptide-based imaging agents have become workhorses of oncology diagnostics. The somatostatin receptor-targeting agents (OctreoScan, Netspot, Detectnet) allow physicians to locate neuroendocrine tumors anywhere in the body. Lumisight, approved in 2024, takes a different approach: the peptide prodrug is optically inactive until cleaved by tumor-associated enzymes, making residual cancer tissue glow during surgery.
Dermatology and Sexual Health
| Generic Name | Brand Name(s) | Approval Year | Indication | Manufacturer |
|---|---|---|---|---|
| Bremelanotide | Vyleesi | 2019 | Hypoactive sexual desire disorder (premenopausal women) | Palatin Technologies |
| Afamelanotide | Scenesse | 2019 | Erythropoietic protoporphyria (phototoxicity prevention) | Clinuvel |
Bremelanotide is a cyclic heptapeptide melanocortin agonist --- a close relative of the research peptide Melanotan II but with a more targeted pharmacology. Read more in our PT-141 profile.
Recent Approvals: 2023--2026
The pace of peptide drug approvals has accelerated. Here are the most recent additions.
| Year | Drug | Brand | Indication | Significance |
|---|---|---|---|---|
| 2023 | Tirzepatide | Zepbound | Chronic weight management | First dual GIP/GLP-1 agonist for obesity |
| 2023 | Trofinetide | Daybue | Rett syndrome | First-ever Rett syndrome treatment; oral tripeptide |
| 2023 | Zilucoplan | Zilbrysq | Generalized myasthenia gravis | First subcutaneous complement inhibitor peptide |
| 2023 | Motixafortide | Aphexda | Stem cell mobilization (multiple myeloma) | First peptide CXCR4 antagonist approved |
| 2024 | Palopegteriparatide | Yorvipath | Hypoparathyroidism | First treatment specifically for hypoparathyroidism; PEGylated PTH prodrug |
| 2024 | Pegulicianine | Lumisight | Breast cancer fluorescence imaging | First peptide-based intraoperative fluorescence agent |
| 2025 | Elamipretide | Forzinity | Barth syndrome | First mitochondria-targeted peptide drug; first Barth syndrome treatment |
| 2025 | Semaglutide (oral, 25 mg) | Wegovy (oral) | Weight management / CV risk reduction | First oral GLP-1 for weight loss |
The Approval Timeline: Peptide Drugs by Decade
| Decade | Approximate Approvals | Notable Milestones |
|---|---|---|
| 1920s--1950s | 2--5 | Insulin (1922/1982 recombinant), vasopressin, ACTH |
| 1960s--1970s | 5--8 | Oxytocin (synthetic), desmopressin, calcitonin |
| 1980s | 8--12 | Leuprolide, goserelin, octreotide, recombinant human insulin |
| 1990s | 10--15 | Glatiramer acetate, ganirelix, cetrorelix, eptifibatide |
| 2000s | 15--20 | Exenatide, enfuvirtide, teriparatide, ziconotide, bivalirudin |
| 2010s | 20--25 | Liraglutide, semaglutide, tirzepatide (2022 technically), linaclotide, teduglutide, multiple GnRH agents |
| 2020s (to date) | 15+ | Tirzepatide, trofinetide, pegcetacoplan, zilucoplan, motixafortide, elamipretide, Lutathera, palopegteriparatide |
The highest number of peptide approvals occurred between 2020 and 2024, driven by metabolic disease (GLP-1 drugs), rare diseases, and oncology.
FAQ
How many peptide drugs are FDA-approved?
The commonly cited figure is around 80--100, depending on how you count insulin analogs, reformulations, and peptide-adjacent molecules like cyclic lipopeptide antibiotics. The THPdb2 database catalogs 85 distinct peptide/polypeptide drugs and 380 drug variants (different formulations and brand names).
What is the most prescribed peptide drug?
By prescription volume, insulin remains number one globally. By revenue growth, semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the clear leaders, with combined annual sales exceeding $40 billion.
Are compounded peptides the same as FDA-approved peptides?
No. Compounded peptides are prepared by compounding pharmacies and are not subject to the same manufacturing standards, testing, or approval processes as FDA-approved drugs. The FDA has increasingly restricted compounding of certain peptides, including placing BPC-157 and TB-500 on its Category 2 list of substances with safety concerns. For more, see our article on the FDA compounding crackdown.
Which peptide drug was approved most recently?
As of early 2026, the most recent peptide approvals include elamipretide (Forzinity) for Barth syndrome and oral semaglutide 25 mg (Wegovy oral) for weight management, both in 2025.
How many peptide drugs are currently in clinical trials?
Over 150 peptides are in active clinical trials, with another 400--600 in preclinical development. ClinicalTrials.gov lists roughly 1,400 trials involving peptide therapeutics, and 38 peptide drugs were in Phase III trials as of 2024. For help navigating clinical trial data, see our guide to peptide databases and research resources.
Can I look up the approval history of a specific peptide drug?
Yes. The FDA's Drugs@FDA database (accessdata.fda.gov/scripts/cder/daf) provides approval letters, labeling, and review documents for every approved drug. The Purdue CDEK database also maintains a searchable list of FDA-approved peptide drugs.
Why are some peptides "FDA-approved" for one condition but used off-label for others?
FDA approval is indication-specific. A drug approved for diabetes (like semaglutide/Ozempic) can be legally prescribed off-label for weight loss by a physician, even before it received a separate obesity approval (Wegovy). Off-label prescribing is legal and common, but the evidence supporting it varies. Always discuss the evidence base with your doctor --- our guide on how to talk to your doctor about peptides can help.
The Bottom Line
The FDA-approved peptide drug list spans more than a century of pharmaceutical development, from the isolation of insulin in the 1920s to the mitochondria-targeted elamipretide in 2025. The trend line is clear: peptide approvals are accelerating, driven by advances in peptide chemistry (PEGylation, acylation, cyclization), oral delivery technology, and a deeper understanding of peptide hormone biology.
The GLP-1 revolution in particular has brought peptide drugs into mainstream awareness. But approved peptide drugs extend far beyond weight loss --- into oncology, rare diseases, pain management, infectious disease, and diagnostics.
If you're exploring peptide therapy options, the critical distinction to understand is between FDA-approved medications (manufactured to strict standards, backed by clinical trials) and unapproved peptides (research-grade, compounded, or imported without regulatory oversight). For guidance on navigating this terrain, see our articles on what peptide therapy is and how it works and how to choose a peptide therapy clinic.
References
-
2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2025;18(3):291. https://pmc.ncbi.nlm.nih.gov/articles/PMC11945313/
-
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2026;19(2):244. https://www.mdpi.com/1424-8247/19/2/244
-
FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond. Journal of Peptide Science. 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/psc.3627
-
Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and alpha-MSH Realms. Biomolecules. 2024;14(3):264. https://pmc.ncbi.nlm.nih.gov/articles/PMC10968328/
-
THPdb2: compilation of FDA approved therapeutic peptides and proteins. Drug Discovery Today. 2024. https://www.sciencedirect.com/science/article/abs/pii/S1359644624001727
-
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduction and Targeted Therapy. 2024. https://www.nature.com/articles/s41392-024-02107-5
-
Purdue CDEK FDA Peptide Approvals Database. https://cdek.pharmacy.purdue.edu/fda-approvals/Peptide/
-
THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12(7):e0181748. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181748
-
FDA Approves YORVIPATH (palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults. Ascendis Pharma press release. August 12, 2024. https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-yorvipathr-palopegteriparatide-first-and-only
-
Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/